Business Development Remains Top Priority For Ipsen
Posts Solid Q4 Results Despite Somatuline Decline
CEO David Loew tells Scrip that Ipsen’s prodigious dealmaking over the past couple of years is set to continue, on top of the acquisition of Albireo announced last month.
